{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T06:19:32Z","timestamp":1703225972114},"reference-count":53,"publisher":"Wiley","issue":"S6","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Based on numerous trials, oral tetracyclines and most commonly their second\u2010generation derivative doxycycline have become the main pillar in systemic rosacea treatment. However, the only preparation that has been approved so far in this setting is 40\u00a0mg doxycycline in an anti\u2010inflammatory dosage and with a modified release formulation. With the introduction of this once\u2010daily, non\u2010antibiotic dosing of doxycycline, oral therapy is more commonly prescribed as first\u2010line treatment in moderate to severe papulopustular rosacea. In addition, topical and oral strategies are often used in combination due to the more substantial improvements compared to monotherapy. Although several other non\u2010approved oral agents like macrolides, isotretinoin, and carvedilol have been evaluated for systemic treatment and showed promising results, yet the experience with these drugs in rosacea is limited, and thus they should be reserved for special situations.<\/jats:p>","DOI":"10.1111\/ddg.13141","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T12:55:39Z","timestamp":1479732939000},"page":"29-37","source":"Crossref","is-referenced-by-count":15,"title":["State of the art: systemic rosacea management"],"prefix":"10.1111","volume":"14","author":[{"given":"M","family":"Schaller","sequence":"first","affiliation":[{"name":"Department of Dermatology T\u00fcbingen University Hospital  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Sch\u00f6fer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology University Hospital Goethe\u2010University  Frankfurt\/M Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Homey","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Faculty University of D\u00fcsseldorf  D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Gieler","sequence":"additional","affiliation":[{"name":"Clinics for Dermatology and Allergology Justus\u2010Liebig\u2010University  Giessen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, HELIOS Hospital Wuppertal Witten\/Herdecke University  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TA","family":"Luger","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital M\u00fcnster  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Ludwig\u2010Maximilian University  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Department of Dermatology and\u00a0UCD Charles Institute for\u00a0Translational Dermatology \u00a0University College Dublin  Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"e_1_2_16_2_1","first-page":"18","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies","volume":"93","author":"Del Rosso JQ","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.027"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03751.x"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13143"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12101_suppl"},{"key":"e_1_2_16_7_1","first-page":"1","article-title":"Systemic Therapy for Rosacea","volume":"12","author":"Baldwin HE","year":"2007","journal-title":"Skin Therapy Letter"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90376-X"},{"issue":"6","key":"e_1_2_16_9_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ddg.13143","article-title":"Rosacea Management: Update on general measures and topical treatment options. 2016","volume":"14","author":"Schaller M","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.004"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"e_1_2_16_12_1","first-page":"411","article-title":"Second\u2010generation tetracyclines, a dermatologic overview: clinical uses and pharmacology","volume":"48","author":"Maibach H","year":"1991","journal-title":"Cutis"},{"key":"e_1_2_16_13_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2340\/0001555572178179","article-title":"Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline","volume":"72","author":"Akamatsu H","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.567"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"issue":"6","key":"e_1_2_16_16_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ddg.13139","article-title":"Pathogenesis and clinical presentation of rosacea as a key for a symptom\u2010oriented therapy. 2016","volume":"14","author":"Reinholz M","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_16_17_1","first-page":"149","article-title":"Treatment of rosacea with doxycycline monohydrate","volume":"66","author":"Bikowski JB","year":"2000","journal-title":"Cutis"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07345_supp.x"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03445.x"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/17469872.2.5.523"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_16_22_1","first-page":"664","article-title":"Anti\u2010inflammatory dose doxycycline in the treatment of rosacea","volume":"8","author":"Del Rosso JQ","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2003.03014.x"},{"key":"e_1_2_16_24_1","first-page":"641","article-title":"Combined effect of anti\u2010inflammatory dose doxycycline (40\u2010mg doxycycline, usp monohydrate controlled\u2010release capsules) and metronidazole topical gel 1 % in the treatment of rosacea","volume":"6","author":"Fowler JF","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_16_25_1","first-page":"573","article-title":"Comparison of anti\u2010inflammatory dose doxycycline versus doxycycline 100\u00a0mg in the treatment of rosacea","volume":"7","author":"Del Rosso JQ","year":"2008","journal-title":"J Drugs in Dermatol"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.3.541"},{"issue":"9","key":"e_1_2_16_27_1","first-page":"5S","article-title":"Clinical implications of the immunomodulatory effects of macrolides","volume":"117","author":"Tamaoki J","year":"2004","journal-title":"Am J Med"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02322.x"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00301.x"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.01958.x"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.4065\/74.6.613"},{"key":"e_1_2_16_32_1","first-page":"54","article-title":"Use of oral isotretinoin in the management of rosacea","volume":"4","author":"Park H","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.033"},{"key":"e_1_2_16_35_1","unstructured":"NikolowskiJ PlewigG.Oral treatment of rosacea with 13\u2010cis\u2010retinoic acid Hautarzt1981;32:575\u201384."},{"key":"e_1_2_16_36_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2340\/00015555641521","article-title":"13\u2010cis\u2010Retinoic acid in rosacea. Clinical and laboratory findings","volume":"64","author":"Schmidt JB","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04533.x"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1984.tb00842.x"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.111"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1064456"},{"key":"e_1_2_16_41_1","first-page":"301","volume-title":"Acne and Related Disorders","author":"Irvine C","year":"1989"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0888"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.204"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.017"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.041"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71750-7"},{"key":"e_1_2_16_47_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1997.03890370055009","article-title":"Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline","volume":"133","author":"Quarterman MJ","year":"1997","journal-title":"Arch Dermatol"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2011.07723_suppl.x"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000051"},{"key":"e_1_2_16_50_1","unstructured":"Personal communication by Prof. Martin Schaller based on an unpublished observation."},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03132.x"},{"key":"e_1_2_16_52_1","first-page":"607","article-title":"Efficacy of topical azelaic acid (AzA) gel 15 % plus oral doxycycline 40 mg versus metronidazole gel 1 % plus oral doxycycline 40 mg in mild\u2010to\u2010moderate papulopustular rosacea","volume":"9","author":"Del Rosso JQ","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_16_53_1","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15 % gel in combination with oral doxycycline as initial therapy and azelaic acid 15 % gel as maintenance monotherapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"e_1_2_16_54_1","first-page":"16","article-title":"Effectiveness and safety of doxycycline 40 mg (30\u2010mg immediate\u2010release and 10\u2010mg delayed\u2010release beads) once daily as add\u2010on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community\u2010based trial","volume":"86","author":"Del Rosso JQ","year":"2010","journal-title":"Cutis"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13141","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T02:28:13Z","timestamp":1696040893000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":53,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ddg.13141"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13141","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}